Symbols

NMTR(Delisted)

9 Meters·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NMTR

9 Meters Biopharma, Inc.

A clinical-stage company pioneering novel treatments for rare or debilitating digestive diseases

Industry

Established Date

Listing Date

07/08/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.9meters.com

Security Type

Common stock

Office address

4509 Creedmoor Road, Suite 600, Raleigh, NC 27612

Business

Introduction

9 Meters Biopharma, Inc., is a clinical-stage company pioneering new treatments for people suffering from rare digestive diseases, gastrointestinal diseases with unmet needs, and debilitating diseases caused by biological factors in the gut. The company's pipeline includes vurolenatide, a patented Phase 3 long-acting GLP-1 agonist for SBS, and a strong pipeline of early stage drug candidates for undisclosed rare diseases or unmet needs.

Company Financials

EPS

NMTR has released its 2023 Q1 earnings. EPS was reported at -1.02, versus the expected -0.78, missing expectations. The chart below visualizes how NMTR has performed over recent quarters, highlighting trends in earnings surprises.